Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Core Viewpoint - Alterity Therapeutics is advancing ATH434 in late-stage clinical development for Multiple System Atrophy (MSA), a rapidly progressive neurodegenerative disease with no approved therapies [1][3] Company Overview - Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, particularly MSA and related Parkinsonian disorders [1][10] - The company is preparing to initiate a Phase 3 pivotal trial in MSA, having demonstrated clinically meaningful efficacy in a Phase 2 clinical trial [10] Disease Background - MSA is characterized by motor impairment, autonomic dysfunction, and rapid loss of independence, with symptoms resembling Parkinson's disease, making early diagnosis challenging [2][9] - The disease affects up to 50,000 individuals in the U.S., and there are currently no approved drugs to slow its progression or cure it [9] Clinical Development of ATH434 - ATH434 is an investigational oral therapy designed to redistribute excess iron in the brain, which contributes to neurodegeneration in MSA [3][6] - Positive results from a randomized, double-blind, placebo-controlled Phase 2 clinical trial showed robust clinical efficacy and a favorable safety profile [6][8] - The Phase 2 trial enrolled 77 adults and demonstrated significant improvement on the modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I compared to placebo [8] Research and Biomarkers - The clinical program incorporates biomarkers and advanced neuroimaging to better characterize disease progression and assess therapeutic impact [4] - Biomarkers indicated that both dose levels of ATH434 reduced iron accumulation in MSA-affected brain regions and showed trends in preserving brain volume [8] Awareness and Advocacy - Throughout MSA Awareness Month, the company will share educational information and highlight the experiences of the MSA community, emphasizing the need for continued research [5]